Vertex Pharmaceuticals Inc (VRTX) Quote - XNAS | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Premium

Is it the right time to buy or sell?

Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Vertex Reports Strong Q2 Results; Raising FVE to $266 on Improved Outlook, Shares Remain Undervalued

Equity Analyst Rachel Elfman

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman | Aug 2, 2021

Vertex reported solid second-quarter results that outperformed FactSet consensus estimates, driven by continued strong performance of its cystic fibrosis franchise. We’ve raised our fair value estimate to $266 per share from $259 to reflect an improved 2021 outlook based on stronger than expected cystic fibrosis sales. We maintain our narrow moat rating and continue to view shares as undervalued. Vertex is well-supported by lengthy patent protections extending as far as year 2037 and first-mover status in the lucrative cystic fibrosis market, which underpins the basis of our narrow moat rating.

Read Full Analysis

Company Profile

Business Description

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex’s pipeline includes gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease as well as small-molecule medicines targeting diseases associated with alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease. Vertex also has an expanding research pipeline focused on inflammatory diseases, non-opioid treatments for pain, and genetic and cell therapies for type 1 diabetes and rare diseases.

Contact

50 Northern Avenue
Boston, MA, 02210

T +1 617 341-6100

investorinfo@vrtx.com

Sector Healthcare

Industry Biotechnology

Most Recent Earnings Jun 30, 2021

Fiscal Year End Dec 31, 2021

Stock Type Aggressive Growth

Employees 3,400

Related

33 Undervalued Stocks for the Fourth Quarter

Here are our analysts' top ideas in each sector for the coming quarter.

Susan Dziubinski

Quarter-End Insights

Healthcare Still Looks Pricey

Drug and biotech industries pricing in the risk of policy changes in the U.S., but we don't think there will be a big regulatory impact.

33 Undervalued Stocks for the Third Quarter

Here are our analysts' top ideas in each sector for the coming quarter.

Susan Dziubinski

Quarter-End Insights

Drugmakers, Biotech Pressured by Policy Risk, but We Don't Expect Big Regulatory Changes

We also expect a return to more elective procedures.

10 Promising Stocks to Consider

These companies are growing their competitive advantages--and their stocks are undervalued.

Susan Dziubinski

Digging Into Fidelity Contrafund

We reveal how the fund’s underlying holdings stack up on 11 measures of equity-related risk.

Premium Article

5 Stocks With More Room to Run

Premium Exclusive: These stocks have momentum on their side yet still look undervalued by our metrics.

Susan Dziubinski

We See This Firm Emerging as a Rare-Disease Powerhouse

Vertex Pharmaceutical's monopoly in the cystic fibrosis market forms the basis of our narrow-moat rating, and we expect that moat to continue to grow.

5 Stocks With More Room to Run

These stocks have gained twice as much as the S&P 500 in 2017 yet remain undervalued according to our metrics.

Susan Dziubinski

Stock Strategist

Vertex Is a Rare-Disease Powerhouse

The shares currently look undervalued ahead of further drug approval.

Weekly Wrap: Utilities Still Have Opportunity

Trump's review of the Clean Power Plan shouldn't alter the long-term move toward natural gas and renewables. Plus, active management shakeup at BlackRock, and Vertex soars after trial.

Morningstar.com

Stock Analyst Update

Even After Rally, Vertex Undervalued

Shares soared following favorable news from the narrow-moat drugmaker's pivotal trials, yet we see further upside.

Stock Analyst Update

Why We're Still Bullish on Vertex Despite Low Guidance

The market is underestimating Vertex's entrenched position in the cystic fibrosis market supported by a robust pipeline of next-generation products.

The Year in U.S. Equity Funds: Resilient in a Tumultuous 2016

In a year of unexpected events, U.S. stocks rose again with small caps outperforming for the first time since 2013.

Investing Specialists

Morningstar Runs the Numbers

We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended Oct. 15.

Morningstar.com

Stock Analyst Update

Vertex: News Creates Opportunity in Shares

Despite a slowdown in Orkambi refills, this narrow-moat drugmaker's burgeoning cystic fibrosis portfolio should create a dominant franchise in this lucrative rare disease market.

Stock Picks from Morningstar Analysts

A trio of Morningstar analysts share their outlooks for and opportunities in the healthcare, consumer, and basic materials sectors.

Susan Dziubinski

The Picks Panel: Best Ideas From Morningstar Analysts

Whether you need to fill a hole in your retirement portfolio or want to find a world-class company at a bargain-basement stock price, a trio of Morningstar specialists share their shopping lists of topnotch candidates.

Morningstar.com

Picks from Morningstar's Senior Researchers

Morningstar's Russ Kinnel, Ben Johnson, and Elizabeth Collins discuss their favorite investment ideas among mutual funds, ETFs, and stocks.

We Think This Narrow-Moat Biotech Is Cheap

With an increasingly dominant position in cystic fibrosis, Vertex’s competitive position is strong, and the stock's sell-off has been unwarranted.

Stefan Quenneville, CFA

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.